1-15 of 61
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CEImproving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE
Samir Dalia, MD
Christopher Jurief
Menin Inhibitors: Biologic and Clinical Rationale
MinuteCE®Menin Inhibitors: Biologic and Clinical Rationale
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Emerging Directions in Menin-Directed AML Therapy
MinuteCE®Emerging Directions in Menin-Directed AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
- advertisement
Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
MinuteCE®Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
Ghayas Issa, MD
Amir Fathi, MD
Managing Adverse Events Associated With Menin Inhibitors
MinuteCE®Managing Adverse Events Associated With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
MinuteCE®Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
Molecular Profiling as a Cornerstone of Precision AML Therapy
MinuteCE®Molecular Profiling as a Cornerstone of Precision AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Ongoing Clinical Trials in AML With Menin Inhibitors
MinuteCE®Ongoing Clinical Trials in AML With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
- advertisement
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
MinuteCE®Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
